Drug
HMPL-760
HMPL-760 is a pharmaceutical drug with 3 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
1(33%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_3
1
33%
Ph phase_1
2
67%
Phase Distribution
2
Early Stage
0
Mid Stage
1
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
Phase 3Large-scale testing
1(33.3%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
50.0%
1 of 2 finished
Non-Completion Rate
50.0%
1 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Completed(1)
Terminated(1)
Detailed Status
Completed1
Recruiting1
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 12 (66.7%)
Phase 31 (33.3%)
Trials by Status
completed133%
recruiting133%
withdrawn133%
Recent Activity
1 active trials
Showing 3 of 3
recruitingphase_3
A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
NCT07409428
completedphase_1
HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
NCT05190068
withdrawnphase_1
HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL
NCT05176691
Clinical Trials (3)
Showing 3 of 3 trials
NCT07409428Phase 3
A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
NCT05190068Phase 1
HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
NCT05176691Phase 1
HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3